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Recent studies have suggested the relevance of different
energy metabolic pathways in the balance between protec-
tive T cell immunity and T cell anergy in tumors. We and
others have suggested the role of the depletion of the non-
essential amino acid L-arginine as a mechanism for the
induction of T cell suppression in tumors. Therefore,
we hypothesize that it is possible to metabolically regulate
T cell responses simply through the modulation of
L-arginine. In this study, we aimed to determine the effect
of a pegylated form of the human L-arginine-metabolizing
enzyme arginase I (peg-Arg I) in T cell responses. Activa-
tion of antigen-specific CD4+ and CD8+ T cells in the pre-
sence of peg-Arg I prevented cell proliferation and
production of IFNg in vitro and in vivo. Similarly, peg-Arg I
impaired proliferation and IFNg production in T cells acti-
vated with PMA/Ionomycin, suggesting that the effect of
peg-Arg I was independent of T cell receptor (TCR) signal-
ing. In fact, the anti-proliferative effect induced by peg-Arg
I correlated with an arrest of T cells in the G0-G1 phase of
the cell cycle, a decreased expression of cyclin D3 and cdk4,
and a major inhibition of de novo translation. Interestingly,
treatment of T cells with peg-Arg I did not impair the
expression of activation markers CD25, CD69, and the pro-
duction of IL-2, which correlated with an intact mitochon-
drial biogenesis. As a result, peg-Arg I did not have an
effect in oxygen consumption (OCR) by mitochondrial
respiration, but significantly blocked glycolytic pathways in
activated T cells. Furthermore, peg-Arg I treated T cells
increased the expression of genes associated with integrated
stress responses (IRS) and arrest in translation including
GCN2, Chop, and Atf4. In fact, GCN2 was a major media-
tor of the effects induced by peg-Arg I. Then, we tested the
effect of peg-Arg I in mouse models of graft versus host dis-
ease (GVHD) and inflammatory bowel disease (IBD), both
mediated through activated T cells. Peg-Arg I significantly
extended the survival of mice in these 2 disease models,
which associated with a decreased production of IFNg.
Altogether the results suggest the potential effect of the
modulation of the metabolism of L-arginine as a mean to
modulate T cell responses. Continuation of this study will
advance in the understanding of the metabolic effects of
L-arginine in T cell function, which could enable the devel-
opment of therapies to modulate T cell responses in trans-
plantation or autoimmunity.
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